anti-Coagulation Factor X (F10) Antikörper

F10 encodes the vitamin K-dependent coagulation factor X of the blood coagulation cascade. Zusätzlich bieten wir Ihnen Coagulation Factor X Kits (72) und Coagulation Factor X Proteine (31) und viele weitere Produktgruppen zu diesem Protein an.

Alle Antikörper anzeigen Gen GeneID UniProt
F10 2159 P00742
F10 14058 O88947
F10 29243 Q63207
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen
  • orders@antikoerper-online.de

Top anti-Coagulation Factor X Antikörper auf antikoerper-online.de

Showing 10 out of 253 products:

Katalog Nr. Reaktivität Wirt Konjugat Applikation Bilder Menge Anbieter Lieferzeit Preis Details
Rind (Kuh) Kaninchen Unkonjugiert WB WB Suggested Anti-F10 Antibody Titration:  0.2-1 ug/ml  Positive Control:  721_B cell lysate 100 μL Anmelden zum Anzeigen 2 bis 3 Tage
$319.00
Details
Human Kaninchen Unkonjugiert ELISA, WB Western blot analysis of extracts from rat liver cells, using FA10 (activated heavy chain,Cleaved-Ile235) Antibody. The lane on the right is treated with the synthesized peptide. 100 μg Anmelden zum Anzeigen 2 bis 3 Tage
$302.50
Details
Human Kaninchen Unkonjugiert ELISA, WB Western blot analysis of extracts from A549 cells, treated with etoposide 24uM 24h, using FA10 (light chain,Cleaved-Ala41) Antibody. The lane on the right is treated with the synthesized peptide. 100 μg Anmelden zum Anzeigen 2 bis 3 Tage
$302.50
Details
Human Kaninchen Unkonjugiert ICC, IF, IHC (p), IHC, WB Western Blot: Coagulation Factor X Antibody [NBP1-33320] - A. 30 ug GL261 whole lysate/extract, B. 30 ug C8D30 whole cell lysate/extract 10% SDS-PAGE gel, antibody dilution 1:1000. Western Blot: Coagulation Factor X Antibody [NBP1-33320] - Sample (30 ug of whole cell lysate) A: Hela 10% SDS PAGE; antibody diluted at 1:1000. 0.1 mL Anmelden zum Anzeigen 8 bis 11 Tage
$516.98
Details
Human Kaninchen Unkonjugiert WB   200 μL Anmelden zum Anzeigen 13 bis 14 Tage
$487.50
Details
Human Kaninchen Unkonjugiert EIA, WB 0.4 mL Anmelden zum Anzeigen 6 bis 8 Tage
$484.00
Details
Human Kaninchen Unkonjugiert FACS, IHC (p), WB Western blot analysis of F10 antibody (C-term) (ABIN390688) in 293 cell line lysates (35 µg/lane). F10 (arrow) was detected using the purified polyclonal antibody. F10 Antibody (C-term) (ABIN390688) IHC analysis in formalin fixed and paraffin embedded human hepatocarcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining 400 μL Anmelden zum Anzeigen 10 bis 11 Tage
$385.00
Details
Hund Kaninchen Unkonjugiert WB 50 μg Anmelden zum Anzeigen 11 bis 14 Tage
$551.83
Details
Human Kaninchen Unkonjugiert ICC, IF, IHC (p), WB IHC-P Image Immunohistochemical analysis of paraffin-embedded A549 xenograft, using Factor X, antibody at 1:500 dilution. ICC/IF Image Immunofluorescence analysis of methanol-fixed HeLa, using Factor X, antibody at 1:200 dilution. 100 μL Anmelden zum Anzeigen 3 bis 4 Tage
$466.18
Details
Human Kaninchen Unkonjugiert ELISA, IHC, WB Western blot analysis of extracts of HepG2, using F10 antibody. The lane on the left is treated with the antigen-specific peptide. ABIN6276681 at 1/100 staining Mouse liver tissue by IHC-P. The sample was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The sample was then blocked and incubated with the antibody for 1.5 hours at 22¡ãC. An HRP conjugated goat anti-rabbit antibody was used as the secondary 100 μL Anmelden zum Anzeigen 11 bis 12 Tage
$390.77
Details

Weitere Antikörper gegen Coagulation Factor X Interaktionspartner

Human Coagulation Factor X (F10) Interaktionspartner

  1. The identification of 11 novel F10 mutations provides a substantial contribution to the mutations known to cause FXD.

  2. F10 mutation spectrum in Pakistan is heterogeneous as seen in other populations

  3. Gla-domainless factor Xa binds to TFPI and restores ex vivo coagulation in hemophilia plasma

  4. An antidote could promptly neutralize the anticoagulant effects of both FXa inhibitors. Our results suggest that drugs and aptamers with shared targets can be combined to exert more specific and potent effects than either agent alone

  5. model predicts that small vesicles promote activation of FX by the extrinsic tenase significantly better than large vesicles

  6. miR-24 was overexpressed in major trauma-induced coagulopathy (TIC) patients. The negative correlation of miR-24 with FX suggested the possibility that miR-24 might inhibit the synthesis of FX during TIC.

  7. this study demonstrated that thrombin and factor Xa cleavage sites on HEV pORF1 are obligatory for HEV replication.

  8. zymogen-like factor Xa variants are conformationally dynamic and ligands such as its cofactor, factor Va, stabilize the molecule rescuing procoagulant activity. At the site of vascular injury, the variants in the presence of factor Va serve as effective prohemostatic agents.

  9. Data suggest that, for all coagulation proteins tested (prothrombin, factor X, activated factor VII, activated protein C), tighter binding to lipid bilayers (lower Kd) is observed as the proportion of anionic phospholipid increases. These studies were conducted in high-throughput screening using phospholipid bilayers in nanodiscs with multiplexed silicon photonic sensor (micro-ring resonator) array technology.

  10. A coagulation initiating pathway is revealed in which the TF-FVIIa-nascent FXa complex activates FVIII apart from thrombin feedback.

  11. Data suggest oxidized lipid vesicles with phosphatidylserine/polyunsaturated fatty acids promote inactivation of ZPI-PZ complex or free ZPI; binding of PZ-complexed or free ZPI to oxidized vesicles mediates inactivation of ZPI (an inhibitor of FXa); blocking heparin- (anticoagulant-)binding site on ZPI interferes with binding to lipid or PZ. (ZPI = protein Z-dependent protease inhibitor; PZ = protein Z; FXa = factor Xa)

  12. Factor Va reduced by 100-fold the apparent Kd of myosin for factor Xa (Kd approximately 0.48 nM), primarily by reducing koff, indicating formation of a stable ternary complex of myosin:Xa:Va.

  13. PTX2 was identified PTX2 as a novel partner for FX, and both proteins cooperated to prevent their SR-AI-mediated uptake by macrophages.

  14. annexin A2 contributes to lung injury and fibrotic disease by mediating the fibrogenic actions of FXa.

  15. Individuals suffering from relapsing-remitting and secondary progressive multiple sclerosis had significantly higher prothrombin and factor X levels than healthy donors, whereas levels were unchanged in primary progressive MS and neuromyelitis optica patients.

  16. Low concentrations of TF and exogenous FXIa, each too low to elicit a burst in thrombin production alone, act synergistically when in combination to cause substantial thrombin production.

  17. A family with factor X deficiency from Argentina displayed a compound heterozygous proband having the combination of a new mutation with an already known one, and homozygous children.

  18. analysis of how physiological concentrations of Tissue factor pathway inhibitor inhibit FXa

  19. According to our study, compounds 1a, 1g and 1s displayed evident FXa inhibitory activity and excellent selectivity over thrombin in in vitro inhibition activities studies.

  20. This study was conducted to assess the spectrum of factor X gene mutation in Iranian patients with congenital factor X deficiency (FXD). Most molecular studies found a diversity in factor X disease causing mutations in Iranian patients. Like other parts of the world, the majority of mutations in Iranian patients were missense mutations, but splice-site mutations were relatively common. [review]

Mouse (Murine) Coagulation Factor X (F10) Interaktionspartner

  1. PTX2 was identified PTX2 as a novel partner for FX, and both proteins cooperated to prevent their SR-AI-mediated uptake by macrophages.

  2. annexin A2 contributes to lung injury and fibrotic disease by mediating the fibrogenic actions of FXa.

  3. Enhanced FXa and PAR2 exacerbate DN and that both are promising targets for preventing diabetic nephropathy.

  4. Macrophages regulate FX plasma levels in an SR-AI-dependent manner.

  5. Factor Xa has a role in inhibiting HMGB1-induced septic responses in human umbilical vein endothelial cells and in mice

  6. Selective inhibition of FXa improves the left ventricular function during CVB3-induced myocarditis and seems to be associated with an improved myocardial remodeling.

  7. Activated factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from lipopolysaccharide-stimulated myeloid cells.

  8. Differential effects of murine and human factor X on adenovirus transduction via cell-surface heparan sulfate.

  9. There was no detectable increase in plasma levels of mouse FX after active-site inhibited human APC administration to mice overexpressing human EPCR. FX does not effectively interact with EPCR in vivo, at least in regards to the mouse system.

  10. investigation of role of F10a in progression of diabetic nephropathy: data from studies using inhibitor of F10a suggest that F10a does play a role in development of proteinemia, glomerular hypertrophy, and protein deposition in kidney of db/db mice

  11. Data suggest that tissue factor and factor V induction by LPS may in part accelerate mesangioproliferative glomerulonephritis through activation of factor X and downstream proinflammatory and procoagulant mechanisms.

  12. Gene targeting of tissue factor, factor X, and factor VII in mice: their involvement in embryonic development

  13. Factor Xa functions in airway remodeling in asthma by stimulating mucin production, through regulation of amphiregulin expression and collagen deposition.

  14. Complete absence of FX is incompatible with murine survival. Minimal FX activity as low as 1-3% is sufficient to rescue the lethal phenotype.

  15. Results show that although factor Xa induces p42/44 MAP Kinase phosphorylation in endothelial cells, it has no direct effect on endothelial cell proliferation, protein synthesis and tube formation.

  16. expression of coagulation factor X (FX) is locally increased in fibrotic lung tissue, with marked immunostaining associated with bronchial and alveolar epithelia

Cow (Bovine) Coagulation Factor X (F10) Interaktionspartner

  1. Identify potential phosphatidylserine-specific binding sites in the membrane binding domain of coagulation factor X.

  2. Data suggest factor Xa (FXa) and factor Va (FVa) compete to bind FXa on both PS model membranes and microparticles from activated platelets; this competition between dimerization/prothrombinase complex formation appears to regulate blood coagulation.

  3. thrombin and factor Xa diffusion along the heparin molecule explains the effects of extended heparin chain lengths

  4. Factor Xa (fXa), a key serine protease of the coagulation system, was used as a model enzyme to test the canonical conformation hypothesis.

Zebrafish Coagulation Factor X (F10) Interaktionspartner

  1. These findings as well as the prolonged survival of f10(-/-) mutants will enable us to expand our understanding of the molecular mechanisms of hemostasis, including a platform for screening variants of uncertain significance in patients with F10 deficiency and other coagulation disorders

Coagulation Factor X (F10) Antigen-Profil

Protein Überblick

This gene encodes the vitamin K-dependent coagulation factor X of the blood coagulation cascade. This factor undergoes multiple processing steps before its preproprotein is converted to a mature two-chain form by the excision of the tripeptide RKR. Two chains of the factor are held together by 1 or more disulfide bonds\; the light chain contains 2 EGF-like domains, while the heavy chain contains the catalytic domain which is structurally homologous to those of the other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity.

Genbezeichner und Symbole assoziert mit F10

  • coagulation factor X (F10) Antikörper
  • coagulation factor X (f10) Antikörper
  • coagulation factor X (CpipJ_CPIJ012712) Antikörper
  • coagulation factor X (CpipJ_CPIJ014863) Antikörper
  • coagulation factor X (CpipJ_CPIJ016937) Antikörper
  • coagulation factor X (CpipJ_CPIJ017791) Antikörper
  • Coagulation factor X (fa10) Antikörper
  • coagulation factor 10 L homeolog (f10.L) Antikörper
  • Cf10 Antikörper
  • f10 Antikörper
  • fi12c10 Antikörper
  • fX Antikörper
  • FXA Antikörper
  • wu:fi12c10 Antikörper

Bezeichner auf Proteinebene für F10

Stuart-Prower factor , factor Xa , prothrombinase , stuart factor , coagulation factor 10 , VAP , factor XA light chain , virus activating protease , virus-activating protease , coagulation factor X , vitamin K dependent serine protease , coagulation factor X preproprotein , blood coagulation factor X , Coagulation factor X , coagulation factor 10 L homeolog

GENE ID SPEZIES
2159 Homo sapiens
14058 Mus musculus
29243 Rattus norvegicus
280787 Bos taurus
282670 Danio rerio
395876 Gallus gallus
445942 Takifugu rubripes
452679 Pan troglodytes
476993 Canis lupus familiaris
714132 Macaca mulatta
790961 Ornithorhynchus anatinus
6045845 Culex quinquefasciatus
6048453 Culex quinquefasciatus
6050511 Culex quinquefasciatus
6052088 Culex quinquefasciatus
100008647 Oryctolagus cuniculus
100022394 Monodelphis domestica
100137443 Papio anubis
100380501 Salmo salar
100408094 Callithrix jacchus
100453258 Pongo abelii
100471482 Ailuropoda melanoleuca
100607918 Nomascus leucogenys
100726878 Cavia porcellus
101118624 Ovis aries
398778 Xenopus laevis
Ausgewählte Anbieter für anti-Coagulation Factor X (F10) Antikörper
Haben Sie etwas anderes gesucht?